{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T05:13:20Z","timestamp":1788066800493,"version":"build-2784847793"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI101157"],"award-info":[{"award-number":["R01 AI101157"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jconrel.2017.10.022","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T13:16:02Z","timestamp":1508418962000},"page":"176-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Pre-clinical evaluation of a themosensitive gel containing epothilone B and mTOR\/Hsp90 targeted agents in an ovarian tumor model"],"prefix":"10.1016","volume":"268","author":[{"given":"Dae Hwan","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen S.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2017.10.022_bb0005","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2013.11.030","article-title":"Ovarian cancer screening--current status, future directions","volume":"132","author":"Menon","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"Suppl. 8","key":"10.1016\/j.jconrel.2017.10.022_bb0010","first-page":"viii7","article-title":"Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)","volume":"16","author":"du Bois","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2017.10.022_bb0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/11598890-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics","volume":"51","author":"Hasovits","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2017.10.022_bb0020","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1158\/1078-0432.CCR-12-0261","article-title":"Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer","volume":"18","author":"Chambers","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2017.10.022_bb0025","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1634\/theoncologist.2008-0275","article-title":"The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer","volume":"14","author":"Helm","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.jconrel.2017.10.022_bb0030","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00280-007-0449-0","article-title":"Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model","volume":"60","author":"Vassileva","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2017.10.022_bb0035","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s11095-009-0031-z","article-title":"Drug delivery systems for intraperitoneal therapy","volume":"27","author":"Bajaj","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2017.10.022_bb0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12967-016-1027-1","article-title":"Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment","volume":"14","author":"Papa","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jconrel.2017.10.022_bb0045","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1158\/1078-0432.CCR-13-1115","article-title":"Network analysis identifies an HSP90-central hub susceptible in ovarian cancer","volume":"19","author":"Liu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2017.10.022_bb0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12918-016-0278-z","article-title":"Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer","volume":"10","author":"Andorfer","year":"2016","journal-title":"BMC Syst. Biol."},{"key":"10.1016\/j.jconrel.2017.10.022_bb0055","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jconrel.2015.12.015","article-title":"PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels for drug delivery","volume":"240","author":"Cho","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2017.10.022_bb0060","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3109\/1061186X.2014.931406","article-title":"Thermosensitive poly-(d,l-lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly-(d,l-lactide-co-glycolide) hydrogels for multi-drug delivery","volume":"22","author":"Cho","year":"2014","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2017.10.022_bb0065","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2017.10.022_bb0070","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"Franken","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2017.10.022_bb0075","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2147\/IJN.S95850","article-title":"Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells","volume":"11","author":"Han","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2017.10.022_bb0080","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s11095-016-1968-3","article-title":"Proof-of-concept of polymeric sol-gels in multi-drug delivery and intraoperative image-guided surgery for peritoneal ovarian cancer","volume":"33","author":"McKenzie","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2017.10.022_bb0085","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.polymer.2008.01.027","article-title":"Hydrogels in drug delivery: progress and challenges","volume":"49","author":"Hoare","year":"2008","journal-title":"Polymer"},{"key":"10.1016\/j.jconrel.2017.10.022_bb0090","doi-asserted-by":"crossref","first-page":"8674","DOI":"10.1021\/jacs.6b03995","article-title":"Oligo(lactic acid)n-paclitaxel prodrugs for poly(ethylene glycol)-block-poly(lactic acid) micelles: loading, release, and backbiting conversion for anticancer activity","volume":"138","author":"Tam","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2017.10.022_bb0095","first-page":"2325","article-title":"Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action","volume":"55","author":"Bollag","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2017.10.022_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001279","article-title":"Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy","volume":"2","author":"Estep","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2017.10.022_bb0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/1535-7163.MCT-13-0481","article-title":"Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib","volume":"13","author":"Acquaviva","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2017.10.022_bb0110","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/2101123a0","article-title":"Peritoneal fluid volume and the oestrus cycle in mice","volume":"210","author":"Hartveit","year":"1966","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2017.10.022_bb0115","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.jconrel.2017.10.022_bb0120","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0142-9612(02)00377-0","article-title":"Enzymatic degradation behavior and mechanism of poly(lactide-co-glycolide) foams by trypsin","volume":"24","author":"Cai","year":"2003","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2017.10.022_bb0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0141-3910(00)00152-X","article-title":"Enzymatic degradation of PLA stereocopolymers with predominant d-lactyl contents","volume":"71","author":"Li","year":"2001","journal-title":"Polym. Degrad. Stab."},{"key":"10.1016\/j.jconrel.2017.10.022_bb0130","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2013.00256","article-title":"Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front. Oncol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365917309069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365917309069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T04:35:36Z","timestamp":1537850136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365917309069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":26,"alternative-id":["S0168365917309069"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.10.022","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-clinical evaluation of a themosensitive gel containing epothilone B and mTOR\/Hsp90 targeted agents in an ovarian tumor model","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2017.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}